BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31440722)

  • 1. Changes in drug load during lacosamide combination therapy: A noninterventional, observational study in German and Austrian clinical practice.
    Reinhardt F; Weber YG; Mayer T; Luef G; Joeres L; Tennigkeit F; Dedeken P; De Backer M; Hellot S; Lauterbach T; Webers T; Arnold S
    Epilepsia Open; 2019 Sep; 4(3):409-419. PubMed ID: 31440722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.
    Sake JK; Hebert D; Isojärvi J; Doty P; De Backer M; Davies K; Eggert-Formella A; Zackheim J
    CNS Drugs; 2010 Dec; 24(12):1055-68. PubMed ID: 21090839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study.
    Runge U; Arnold S; Brandt C; Reinhardt F; Kühn F; Isensee K; Ramirez F; Dedeken P; Lauterbach T; Noack-Rink M; Mayer T
    Epilepsia; 2015 Dec; 56(12):1921-30. PubMed ID: 26526971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures.
    Steinhoff BJ; Eckhardt K; Doty P; De Backer M; Brunnert M; Schulze-Bonhage A
    Epilepsy Behav; 2016 May; 58():35-43. PubMed ID: 27054272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lacosamide tolerability in adult patients with partial-onset seizures: Impact of planned reduction and mechanism of action of concomitant antiepileptic drugs.
    Foldvary-Schaefer N; Fong JS; Morrison S; Wang L; Bena J
    Epilepsy Behav; 2016 Apr; 57(Pt A):155-160. PubMed ID: 26956629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice.
    Wu T; Chuang YC; Huang HC; Lim SN; Hsieh PF; Lee WT; Cheng MY; Tsai MH; Jou SB; Chang CW; Hsieh HY; Du X; Hellot S; McClung C; Hung C
    Epilepsy Behav; 2020 Dec; 113():107464. PubMed ID: 33152580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES).
    Rudà R; Houillier C; Maschio M; Reijneveld JC; Hellot S; De Backer M; Chan J; Joeres L; Leunikava I; Glas M; Grant R
    Epilepsia; 2020 Apr; 61(4):647-656. PubMed ID: 32329527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials.
    Chung S; Ben-Menachem E; Sperling MR; Rosenfeld W; Fountain NB; Benbadis S; Hebert D; Isojärvi J; Doty P
    CNS Drugs; 2010 Dec; 24(12):1041-54. PubMed ID: 21090838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive lacosamide in clinical practice: sodium blockade with a difference?
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs.
    Neal A; D'Souza W; Hepworth G; Lawn N; Cook M; Nikpour A
    Epilepsy Behav; 2018 Mar; 80():25-32. PubMed ID: 29396359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive lacosamide--5 years' clinical experience.
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Epilepsy Res; 2014 Oct; 108(8):1385-91. PubMed ID: 25064538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early add-on lacosamide in a real-life setting: results of the REALLY study.
    Villanueva V; Garcés M; López-Gomáriz E; Serratosa JM; González-Giráldez B; Parra J; Rodríguez-Uranga J; Toledo M; López González FJ; Bermejo P; Giner P; Castillo A; Molins A; Campos D; Mauri JÁ; Muñoz R; Bonet M; Serrano-Castro P; del Villar A; Saiz-Díaz RA;
    Clin Drug Investig; 2015 Feb; 35(2):121-31. PubMed ID: 25488477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs.
    Groth A; Wilke T; Borghs S; Gille P; Joeres L
    Ger Med Sci; 2017; 15():Doc09. PubMed ID: 28638313
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
    Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
    Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial.
    Zadeh WW; Escartin A; Byrnes W; Tennigkeit F; Borghs S; Li T; Dedeken P; De Backer M;
    Seizure; 2015 Sep; 31():72-9. PubMed ID: 26362380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study.
    Garcés M; Villanueva V; Mauri JA; Suller A; García C; López González FJ; Rodríguez Osorio X; Fernández Pajarín G; Piera A; Guillamón E; Santafé C; Castillo A; Giner P; Torres N; Escalza I; Del Villar A; García de Casasola MC; Bonet M; Noé E; Olmedilla N
    Epilepsy Behav; 2014 Jul; 36():144-52. PubMed ID: 24922617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy.
    Baulac M; Byrnes W; Williams P; Borghs S; Webster E; De Backer M; Dedeken P
    Acta Neurol Scand; 2017 Apr; 135(4):434-441. PubMed ID: 27714769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain.
    Casas-Fernández C; Martínez-Bermejo A; Rufo-Campos M; Smeyers-Durá P; Herranz-Fernández JL; Ibáñez-Micó S; Campistol-Plana J; Alarcón-Martínez H; Campos-Castelló J
    Drugs R D; 2012 Dec; 12(4):187-97. PubMed ID: 23193979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lacosamide and concomitant use of antiepileptic and other medications in a US population - A retrospective cohort study.
    Kalilani L; Lu C; Pierre-Louis B; Gold M
    Epilepsy Behav; 2017 Jul; 72():51-57. PubMed ID: 28575767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction?
    Novy J; Patsalos PN; Sander JW; Sisodiya SM
    Epilepsy Behav; 2011 Jan; 20(1):20-3. PubMed ID: 21056937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.